A citation-based method for searching scientific literature

Nienke A de Glas, Esther Bastiaannet, Frederiek van den Bos, Simon P Mooijaart, Astrid A M van der Veldt, Karlijn P M Suijkerbuijk, Maureen J B Aarts, Franchette W P J van den Berkmortel, Christian U Blank, Marye J Boers-Sonderen, Alfonsus J M van den Eertwegh, Jan-Willem B de Groot, John B A G Haanen, Geke A P Hospers, Hilde Jalving, Djura Piersma, Rozemarijn S van Rijn, Albert J Ten Tije, Gerard Vreugdenhil, Michel W J M Wouters, Johanneke E A Portielje, Ellen W Kapiteijn. Cancers (Basel) 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.
Curtis H Kugel, Stephen M Douglass, Marie R Webster, Amanpreet Kaur, Qin Liu, Xiangfan Yin, Sarah A Weiss, Farbod Darvishian, Rami N Al-Rohil, Abibatou Ndoye,[...]. Clin Cancer Res 2018
132
50

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka, Taku Okazaki, Tasuku Honjo, Nagahiro Minato. Proc Natl Acad Sci U S A 2002
50

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber, Sandra P D'Angelo, David Minor, F Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I Khushalani, Wilson H Miller, Christopher D Lao,[...]. Lancet Oncol 2015
50

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, Y Iwai, K Bourque, T Chernova, H Nishimura, L J Fitz, N Malenkovich, T Okazaki, M C Byrne,[...]. J Exp Med 2000
50

Cancer immunotherapy comes of age.
Ira Mellman, George Coukos, Glenn Dranoff. Nature 2011
50

Are we over-treating with checkpoint inhibitors?
Sarah Danson, Jane Hook, Helen Marshall, Alexandra Smith, Sue Bell, Simon Rodwell, Pippa Corrie. Br J Cancer 2019
11
50

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, Sunandana Chandra, Christian Menzer, Fei Ye, Shilin Zhao, Satya Das, Kathryn E Beckermann, Lisa Ha,[...]. JAMA Oncol 2018
807
50

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Alice Indini, Lorenza Di Guardo, Carolina Cimminiello, Michele Prisciandaro, Giovanni Randon, Filippo De Braud, Michele Del Vecchio. J Cancer Res Clin Oncol 2019
103
50


Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, Diva R Salomao, Hideto Tamura, Fumiya Hirano, Dallas B Flies, Patrick C Roche, Jun Lu, Gefeng Zhu, Koji Tamada,[...]. Nat Med 2002
50

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima. Front Oncol 2018
462
50

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
Xiaolei Li, Changshun Shao, Yufang Shi, Weidong Han. J Hematol Oncol 2018
127
50

Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy.
A Ezponda Casajús, M Calvo Imirizaldu, J P de Torres Tajes, A García-Baizán, E Castañón Álvarez, D Cano Rafart, I Vivas Pérez, G Bastarrika Alemañ. Radiologia (Engl Ed) 2020
5
50

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Morganna Freeman-Keller, Youngchul Kim, Heather Cronin, Allison Richards, Geoffrey Gibney, Jeffrey S Weber. Clin Cancer Res 2016
494
50


Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.
Evan J Lipson, William H Sharfman, Charles G Drake, Ira Wollner, Janis M Taube, Robert A Anders, Haiying Xu, Sheng Yao, Alice Pons, Lieping Chen,[...]. Clin Cancer Res 2013
372
50

Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma.
Vaianu Leroy, Emilie Gerard, Caroline Dutriaux, Sorilla Prey, Aurelia Gey, Cécile Mertens, Marie Beylot-Barry, Anne Pham-Ledard. Cancer Immunol Immunother 2019
10
50

Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
Shogo Yamaguchi, Ryota Morimoto, Takahiro Okumura, Yuta Yamashita, Tomoaki Haga, Tasuku Kuwayama, Tsuyoshi Yokoi, Hiroaki Hiraiwa, Toru Kondo, Yuki Sugiura,[...]. Can J Cardiol 2018
36
50

Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma.
Panagiotis T Diamantopoulos, Katerina Tsatsou, Olga Benopoulou, Maria Bonou, Amalia Anastasopoulou, Elpida Mastrogianni, Helen Gogas. Melanoma Res 2020
2
50

Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
Matthew T Witmer. Ophthalmic Surg Lasers Imaging Retina 2017
10
50

Sun exposure, phenotypic characteristics, and cutaneous malignant melanoma. An analysis according to different clinico-pathological variants and anatomic locations (Italy).
Luigi Naldi, Andrea Altieri, Gian Lorenzo Imberti, Silvano Gallus, Cristina Bosetti, Carlo La Vecchia. Cancer Causes Control 2005
39
50

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.
Alexandre Reuben, Mariana Petaccia de Macedo, Jennifer McQuade, Aron Joon, Zhiyong Ren, Tiffany Calderone, Brandy Conner, Khalida Wani, Zachary A Cooper, Hussein Tawbi,[...]. Oncoimmunology 2017
31
50

Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha,[...]. N Engl J Med 2015
50

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman, Julie R Brahmer, Donald P Lawrence, Michael B Atkins, John D Powderly,[...]. J Clin Oncol 2014
50

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.
Zhijuan Lin, Xing Chen, Zhifeng Li, Yiming Luo, Zhihong Fang, Bing Xu, Mingzhe Han. PLoS One 2016
23
50

Acute visual loss after ipilimumab treatment for metastatic melanoma.
Melissa A Wilson, Kelly Guld, Steven Galetta, Ryan D Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M Schuchter, Leslie A Fecher. J Immunother Cancer 2016
42
50

Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.
David M Favara, Lavinia Spain, Lewis Au, James Clark, Ella Daniels, Stefan Diem, Dharmisha Chauhan, Samra Turajlic, Nick Powell, James M Larkin,[...]. ESMO Open 2020
8
50

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
J Naidoo, D B Page, B T Li, L C Connell, K Schindler, M E Lacouture, M A Postow, J D Wolchok. Ann Oncol 2015
773
50

Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma.
Héloïse Barailler, Guillemette Salomon, Caroline Dutriaux, Sorilla Prey, Emilie Gérard, Léa Dousset, Cécile Mertens, Marie Beylot-Barry, Nicolas Meyer, Anne Pham-Ledard. J Geriatr Oncol 2020
4
50

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.
Rik J Verheijden, Anne M May, Christian U Blank, Astrid A M van der Veldt, Marye J Boers-Sonderen, Maureen J B Aarts, Franchette W P J van den Berkmortel, Alfonsus J M van den Eertwegh, Jan Willem B de Groot, Jacobus J M van der Hoeven,[...]. ESMO Open 2020
3
50


Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma.
Houssein Safa, Priya Bhosale, Annika Weissferdt, Isabella C Glitza Oliva. Immunotherapy 2020
2
50

Tumor immunotherapy directed at PD-1.
Antoni Ribas. N Engl J Med 2012
414
50

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
50

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F Stephen Hodi, Jacob Schachter, Anna C Pavlick, Karl D Lewis,[...]. Lancet Oncol 2015
50

Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin.
Simone L Park, Anthony Buzzai, Jai Rautela, Jyh Liang Hor, Katharina Hochheiser, Maike Effern, Nathan McBain, Teagan Wagner, Jarem Edwards, Robyn McConville,[...]. Nature 2019
155
50

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
50

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Yucai Wang, Shouhao Zhou, Fang Yang, Xinyue Qi, Xin Wang, Xiaoxiang Guan, Chan Shen, Narjust Duma, Jesus Vera Aguilera, Ashish Chintakuntlawar,[...]. JAMA Oncol 2019
260
50

Brain Tumor Resection in Elderly Patients: Potential Factors of Postoperative Worsening in a Predictive Outcome Model.
Paolo Ferroli, Ignazio Gaspare Vetrano, Silvia Schiavolin, Francesco Acerbi, Costanza Maria Zattra, Marco Schiariti, Matilde Leonardi, Morgan Broggi. Cancers (Basel) 2021
2
50

A Prediction Model for Severe Complications after Elective Colorectal Cancer Surgery in Patients of 70 Years and Older.
Esteban T D Souwer, Esther Bastiaannet, Ewout W Steyerberg, Jan Willem T Dekker, Willem H Steup, Marije M Hamaker, Dirk J A Sonneveld, Thijs A Burghgraef, Frederiek van den Bos, Johanna E A Portielje. Cancers (Basel) 2021
1
100

Octogenarians' Breast Cancer Is Associated with an Unfavorable Tumor Immune Microenvironment and Worse Disease-Free Survival.
Maiko Okano, Masanori Oshi, Swagoto Mukhopadhyay, Qianya Qi, Li Yan, Itaru Endo, Toru Ohtake, Kazuaki Takabe. Cancers (Basel) 2021
1
100

Prediction of Unplanned Hospitalizations in Older Patients Treated with Chemotherapy.
Jaime Feliu, Enrique Espinosa, Laura Basterretxea, Irene Paredero, Elisenda Llabrés, Beatriz Jiménez-Munárriz, Beatriz Losada, Alvaro Pinto, Ana Belén Custodio, María Del Mar Muñoz,[...]. Cancers (Basel) 2021
4
50

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.
Gabor Liposits, Henrik Rode Eshøj, Sören Möller, Stine Brændegaard Winther, Halla Skuladottir, Jesper Ryg, Eva Hofsli, Carl-Henrik Shah, Laurids Østergaard Poulsen, Åke Berglund,[...]. Cancers (Basel) 2021
2
50

Cancer and Aging: Two Tightly Interconnected Biological Processes.
Lieze Berben, Giuseppe Floris, Hans Wildiers, Sigrid Hatse. Cancers (Basel) 2021
11
50

Impact of Androgen Deprivation Therapy Associated to Conformal Radiotherapy in the Treatment of D'Amico Intermediate-/High-Risk Prostate Cancer in Older Patients.
Anne-Laure Couderc, Emanuel Nicolas, Romain Boissier, Mohammed Boucekine, Cyrille Bastide, Delphine Badinand, Dominique Rossi, Benedicte Mugnier, Patrick Villani, Gilles Karsenty,[...]. Cancers (Basel) 2020
4
50

Improving Care for Spanish-Speaking Older Adults with Breast Cancer: Feasibility, Reliability, and Validity of a Self-Administered Spanish Language Geriatric Assessment.
Enrique Soto-Perez-de-Celis, Jessica Vazquez, Heeyoung Kim, Can-Lan Sun, Kemeberly Charles, Ashley Celis, Vani Katheria, Daneng Li, William Dale, Mina S Sedrak. Cancers (Basel) 2021
1
100

A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting.
Samantha Di Donato, Alessia Vignoli, Chiara Biagioni, Luca Malorni, Elena Mori, Leonardo Tenori, Vanessa Calamai, Annamaria Parnofiello, Giulia Di Pierro, Ilenia Migliaccio,[...]. Cancers (Basel) 2021
3
50

Cultural and Ethical Barriers to Cancer Treatment in Nursing Homes and Educational Strategies: A Scoping Review.
Cynthia Filteau, Arnaud Simeone, Christine Ravot, David Dayde, Claire Falandry. Cancers (Basel) 2021
2
50

Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative.
Martine Extermann, Etienne Brain, Beverly Canin, Meena Nathan Cherian, Kwok-Leung Cheung, Nienke de Glas, Beena Devi, Marije Hamaker, Ravindran Kanesvaran, Theodora Karnakis,[...]. Lancet Oncol 2021
19
50

Combination of the G-8 Screening Tool and Hand-Grip Strength to Predict Long-Term Overall Survival in Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy.
Kristian Kirkelund Bentsen, Olfred Hansen, Jesper Ryg, Ann-Kristine Weber Giger, Stefan Starup Jeppesen. Cancers (Basel) 2021
3
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.